Overall survival | Progression-free survival | |||||||
---|---|---|---|---|---|---|---|---|
Lead Author, Year | N | UPSC/clear cell/mixed | Deaths | 3-years OS | Median follow-up (months) | N | Recur, progression or death (N) | 3-years PFS |
Gehrig, 2004 [25] | 9 | 100 %/0 %/0 % | 0 | 100 % | 38 | N/A | 1 | N/A |
aLupe, 2007 [26] | 33 | 33 %/9 %/15 % | 13 | 55 % (2-years) | 21 | 33 | 14 | 55 % (2-years) |
Secord, 2007 [27] | 51 | N/A | 5 | 91 % | 36 | 51 | 13 | 69 % |
aFields, 2008 [28] | 30 | 100 %/0 %/0 % | 10 | 52 % | N/A | 29 | 12 | 54 % |
aLupe, 2009 [16] | 43 | 35 %/7 %/14 % | 14 | 68 % | 30 | 41 | 35 | 53 % |
Secord, 2009 [29] | 45 | 13 %/4 %/29 % | 7 | 88 % | 36 | 45 | 11 | 69 % |
Geller, 2010 [17] | 23 | 52 %/4 %/0 % | 3 | 88 % | 44 | 23 | 5 | 80 % |
aGeller, 2011 [4] | 41 | 9 %/NA/2 % | 7 | 90 % | 28 | 39 | 11 | 71 % |
Abaid, 2012 [5] | 32 | 13 %/9 %/9 % | 3 | N/A | 19 | 8 | 8 | 84 % |
aEinstein, 2012 [6] | 100 %/0 %0 % | 84 % (early stage); 50 % (advanced stage) | 9 | 20 | 20 | N/A | ||
Dogan, 2013 [7] | 11 | 18 %/18 %/0 % | 0 | N/A | 18 | 1 | 5 | N/A |
Lan, 2013 [30] | 35 | N/A | 4 | 82 % | 36 | 35 | 9 | 62 % |
aGeller, 2011 - updated | 41 | 9 %/NA/2 % | 15 | 75 % | 60 | 39 | 15 | 71 % |